147 related articles for article (PubMed ID: 19513942)
1. The mechanism of action of plitidepsin.
Muñoz-Alonso MJ; González-Santiago L; Martínez T; Losada A; Galmarini CM; Muñoz A
Curr Opin Investig Drugs; 2009 Jun; 10(6):536-42. PubMed ID: 19513942
[TBL] [Abstract][Full Text] [Related]
2. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells.
Muñoz-Alonso MJ; González-Santiago L; Zarich N; Martínez T; Alvarez E; Rojas JM; Muñoz A
J Pharmacol Exp Ther; 2008 Mar; 324(3):1093-101. PubMed ID: 18089842
[TBL] [Abstract][Full Text] [Related]
3. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
4. Plitidepsin cellular binding and Rac1/JNK pathway activation depend on membrane cholesterol content.
Suárez Y; González-Santiago L; Zarich N; Dávalos A; Aranda JF; Alonso MA; Lasunción MA; Rojas JM; Muñoz A
Mol Pharmacol; 2006 Nov; 70(5):1654-63. PubMed ID: 16928956
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine.
Erba E; Bassano L; Di Liberti G; Muradore I; Chiorino G; Ubezio P; Vignati S; Codegoni A; Desiderio MA; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2002 May; 86(9):1510-7. PubMed ID: 11986788
[TBL] [Abstract][Full Text] [Related]
6. Novel indoloquinoline derivative, IQDMA, induces G(2)/M phase arrest and apoptosis in A549 cells through JNK/p38 MAPK signaling activation.
Su JC; Lin KL; Chien CM; Lu CM; Chen YL; Chang LS; Lin SR
Life Sci; 2009 Sep; 85(13-14):505-16. PubMed ID: 19699753
[TBL] [Abstract][Full Text] [Related]
7. Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.
Leisch M; Egle A; Greil R
Future Oncol; 2019 Jan; 15(2):109-120. PubMed ID: 30111169
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of the resistance to aplidin in human cancer cells.
González-Santiago L; Alfonso P; Suárez Y; Núñez A; García-Fernández LF; Alvarez E; Muñoz A; Casal JI
J Proteome Res; 2007 Apr; 6(4):1286-94. PubMed ID: 17338558
[TBL] [Abstract][Full Text] [Related]
9. Role of oxidation-triggered activation of JNK and p38 MAPK in black tea polyphenols induced apoptotic death of A375 cells.
Bhattacharya U; Halder B; Mukhopadhyay S; Giri AK
Cancer Sci; 2009 Oct; 100(10):1971-8. PubMed ID: 19594545
[TBL] [Abstract][Full Text] [Related]
10. c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.
Muñoz-Alonso MJ; Álvarez E; Guillén-Navarro MJ; Pollán M; Avilés P; Galmarini CM; Muñoz A
Mar Drugs; 2013 May; 11(5):1677-92. PubMed ID: 23697951
[TBL] [Abstract][Full Text] [Related]
11. Curcumin for chemoprevention of colon cancer.
Johnson JJ; Mukhtar H
Cancer Lett; 2007 Oct; 255(2):170-81. PubMed ID: 17448598
[TBL] [Abstract][Full Text] [Related]
12. Kahalalide F, an antitumor depsipeptide in clinical trials, and its analogues as effective antileishmanial agents.
Cruz LJ; Luque-Ortega JR; Rivas L; Albericio F
Mol Pharm; 2009; 6(3):813-24. PubMed ID: 19317431
[TBL] [Abstract][Full Text] [Related]
13. Induction of mitotic arrest and apoptosis by a novel synthetic quinolone analogue, CWC-8, via intrinsic and extrinsic apoptotic pathways in human osteogenic sarcoma U-2 OS cells.
Chang YH; Yang JS; Kuo SC; Chung JG
Anticancer Res; 2009 Aug; 29(8):3139-48. PubMed ID: 19661327
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of selected natural products as therapeutic agents against cancer.
Banerjee S; Wang Z; Mohammad M; Sarkar FH; Mohammad RM
J Nat Prod; 2008 Mar; 71(3):492-6. PubMed ID: 18302335
[TBL] [Abstract][Full Text] [Related]
15. Heparin and suramin alter plitidepsin uptake via inhibition of GPCR coupled signaling.
Longo-Sorbello GS; Gao H; Mishra PJ; Kamen B; Soto A; Jimeno J; Aracil M; Paz de Paz MF; Bertino JR; Banerjee D
J Chemother; 2009 Nov; 21(5):550-7. PubMed ID: 19933047
[TBL] [Abstract][Full Text] [Related]
16. Plitidepsin: design, development, and potential place in therapy.
Alonso-Álvarez S; Pardal E; Sánchez-Nieto D; Navarro M; Caballero MD; Mateos MV; Martín A
Drug Des Devel Ther; 2017; 11():253-264. PubMed ID: 28176904
[TBL] [Abstract][Full Text] [Related]
17. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases.
Sánchez Y; Calle C; de Blas E; Aller P
Chem Biol Interact; 2009 Nov; 182(1):37-44. PubMed ID: 19720055
[TBL] [Abstract][Full Text] [Related]
18. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction.
Liu XH; Zheng XF; Wang YL
Chin Med J (Engl); 2009 Jul; 122(14):1681-5. PubMed ID: 19719971
[TBL] [Abstract][Full Text] [Related]
19. Plitidepsin to treat multiple myeloma.
Gomes NGM; Valentão P; Andrade PB; Pereira RB
Drugs Today (Barc); 2020 May; 56(5):337-347. PubMed ID: 32406881
[TBL] [Abstract][Full Text] [Related]
20. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
